Every two seconds somebody in the world needs blood.

Only in U.S. 36 thousand units of red blood cells are transfused every day. The need for donor blood increases rapidly which will result in 3 million units of blood deficit by the year 2030.  An artificial blood supply could cover this shortage which will turn into saved lives. For this reason NanoSanguis team is developing innovative and safe red blood cells substitute which can alternate to natural blood.

About us

NanoSanguis is an unique niche where the advanced science meets practical application experience and professional business. The company has its origin in Warsaw University of Technology – the cluster of excellence in polish innovative commercialization. We have started as a team of PhD candidates developing technology of oxygen therapeutics. In December 2015, together with two VC capitals – Start Venture Poland and Giza Polish Ventures, we founded NanoSanguis to bring to the market first safe and effective red blood cell substitute.


NanoSanguis mission is to give safe red blood cell substitute every human in need regardless of their origin, social status and religious beliefs.


We strive to fulfill our mission through the use of scientific and business competencies of our team to commercialize our unique know-how of producing the synthetic oxygen carrier. We will bring to the market the first effective substitute of natural blood for transfusions and organs transport.


Despite of the fact that donor blood transfusions saved many lives, they still have not overcame serious problems. The short shelf life seems to be the most critical. 1.3 million pints of donated blood spoil every year since blood only has a 40 day shelf life. In NanoSanguis we developed the technology for producing synthetic oxygen carrier which is stable for at least one year of storage. Our blood substitute is based on full physiological, buffered fluid composed of balanced minerals compatible with human organism enriched with the source of energy and biomimic microcapsules containing oxygen.


The oxygen therapeutic produced by our team has unique features:

  • nontoxic and bio-inert properties (it does not interfere in metabolic and enzymatic pathways),

  • effective oxygen transport capacity (it can carry several times more oxygen per cubic centimeter than blood, and load/unload oxygen 2 times faster than hemoglobin),

  • unlimited manufacturing capabilities,

  • compatible with all blood types.

Since our product is synthesized in sterile laboratory conditions it can challenge other disadvantage of natural blood- risk of viruses infections. It is critical issue especially in Africa, where in 2004, about 1.2 million units of blood were collected from donors who are considered at high risk for transmitting HIV, hepatitis B or hepatitis C. Moreover, our artificial blood substitute can overcome the ethical issues and religious obstacles connected with natural blood transfusions.

In NanoSanguis we have also recognised another great field of potential application of our oxygen carrier- the transport of organs for transplantations. There is a huge need of improving the organs transport systems. Because of non physiological conditions of transport, many transplantations end with organ failure. Especially in countries where the distances between hospitals and cities are big and the transport lasts hours (U.S.), this problem seems to be crucial. In NanoSanguis we want to apply our oxygen therapeutic to organ transport systems not only to provide the physiological conditions but also to give to the organ the ability for regeneration before transplant.

Our team

Tomasz Ciach

Tomasz Ciach

Founder, Chairman of the Board

Nanotechnology expert.  Professor at the Faculty of Chemical and Processing Engineering, Warsaw University of Technology, head of the Biotechnology and Bioprocessing Division. Author of two technologies that are already in production stage, 12 granted patents and over 50 publications. Founder of BioMedLab research group, consultant in numerous companies (AstraZeneca, Procter and Gamble, Reckit, Adamed, Balton, Galmed). He gives rare, but already brilliant example of how brave ideas become socially and financially valuable.

Stefan Bogusławski

Stefan Bogusławski

Member of the Supervisory Board

For almost 30 years he has been involved in research and consulting in the health market. His professional experience includes many years of managing the Polish branch and the Central European region at IMS Health (IQVIA) and managing research and consulting companies Azyx, Sequence HC Partners and PEX PharmaSequence. He is the author of a number of presentations at many conferences in Poland and abroad as well as publications in the general and professional press on the Polish health market, and the drug market in particular.

Piotr Mierzejewski

Piotr Mierzejewski

Member of the Supervisory Board

Clinical pharmacology specialist, former advisor to the Minister of Health on drug policy. He negotiated Poland’s accession to the EU in the field of pharmacy, responsible for the implementation of EU directives in the field of pharmacy into the Polish legal system. Co-founder of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. Owner of a consulting company cooperating with international pharmaceutical companies in the field of introducing new technologies to the Polish market.

Paweł Ciach

Paweł Ciach

Member of the Supervisory Board

Diplomat and specialist in the field of Marketing, Media Relations, Strategic and Marketing Communications. Graduate of the International Relations at the Institute of National Languages and Civilizations, history and sociology at the School of Social Sciences at the Faculty of History in Paris. He graduated from the Diplomatic Academy in Vienna and post-graduate studies in Management at the University of Warsaw. Worked as a journalist, columnist, commentator, translator and foreign correspondent. Former adviser to the President of the Management Board for Media Relations at the Agricultural Market Agency and President of the Press-Net Board. Trainer of PR in Migut Media, Knowledge, ECU International, Adam Śledański Advertising Academy. He was the director of the office of the Executive Board of the Association for the Employment of Disabled Persons and the chairman of the board of the “Independent. Foundation for the Disabled”. Lecturer at the Institute of Journalism Warsaw School of Advertising.

Sylwia Czarnocka-Śniadała

Sylwia Czarnocka-Śniadała

Organic chemist, PhD

Chemist Researcher, PhD at Warsaw University of Technology Faculty of Chemistry. Strong experienced in working at R&D, Quality Control and Production departments at various companies. Specialist in multi-step syntheses of heterocyclic compounds and pharmaceuticals, purification and analysis techniques. Interested in biotechnology and phytochemistry.

Katarzyna Łęczycka-Wilk

Katarzyna Łęczycka-Wilk

Organic chemist, PhD

Synthesis Specialist, PhD at the Institute of Organic Chemistry, Polish Academy of Sciences. Specializes in the field of carbohydrate and supramolecular chemistry. Current research interests are focused on medical chemistry, especially nano based drug delivery systems.

Joanna Graffstein

Joanna Graffstein

Product Engineer

Biotechnologist. Studies at Warsaw University of Technology (Faculty of Chemistry) and University of Warsaw (Faculty of Biology). Specialist in an artificial oxygen carriers. Experience in working on perfluorocarbon emulsion. Interested in horse riding, mountain climbing, literature of 20th century.

Wojciech Frąckowiak

Wojciech Frąckowiak

Project Manager

Chemical and process engineer. Graduated from West Pomeranian University of Technology and Pomeranian Medical University. Graduate student with a major in Bioengineering at Warsaw University of Technology. Interested in human physiology and artificial organs designing. Movie editor and history enthusiast.

What we do?

oxygen carriers


blood transfusions, transplantations


artificial blood, long-distance organs transport

The research results from the project “Red blood cell substitute” (14‐5712/16, Mazovian Unit of EU Programmes Implementation).

Nano- and microemulsions have found various applications in pharmaceutical and medical areas both in research field as well as in applied solutions for drug delivery or diagnostic agents. However, production of stable and bio- / hemocompatible nanoemulsions are still challenging. New group of ionic surfactants have been synthesized with perfluorohexyl- or perfluorooctyl-groups as hydrophobic tail. The CMC and the parametres of the O/W emulsion (the particle size distribution and the zeta-potential) were determined. The influence of the surfactants on in vitro proliferation of human endothelial cell lines HMEC-1, murine fibroblasts L929 and hemolysis were investigated as characteristic for biocompatibility. Three candidates of surfactants were selected for pre-clinical tests on a small animal model (adult Sprague Dawley rats) on the basis of preliminary studies. This allowed to obtain nanoemulsions with narrow droplets size (average droplet diameter 141 – 147 nm with PDI index 0.059 – 0.065) and showed better stability over time in comparison to the commercially available surfactants. Neither cytotoxic nor hemolytic potential were observed during incubation of obtained fluorosurfactans with model cell lines L929 and HMEC-1 (average cell viability above 85% after incubation with 1% solutions) and erythrocytes (hemolysis rate below 3.1% for all 0.5% solutions). During acute toxicity test on rat model, it was found that all three tested surfactant solutions showed no significant differences in controlled parameters and survival rate with control group (p>0.05). Presented surfactants are dedicated but not limited to emulsification of organic fluorocompounds.

Fulltext of “Fluorosurfactants for medical nanoemulsions, their surface-active and biological properties” by Agata Stefanek, Katarzyna Łęczycka-Wilk, Sylwia Czarnocka-Śniadała, Wojciech Frąckowiak, Joanna Graffstein, Agata Ryżko, Aleksandra Nowak, Tomasz Ciach can be downloaded here [PDF].



NanoSanguis S.A.

NIP: 7010537389
REGON:  363505173

Share capital fully paid up of PLN 185 428,00


[at our domain of]

Rakowiecka 36
02-532 Warsaw, Poland

Contact us

8 + 7 =

[20.12.2019 r.] NanoSanguis S.A. informuje, że w związku z planowaną realizacją prac badawczo – rozwojowych w ramach projektu pt. ,,Substytut czerwonych krwinek – faza Proof of Mechanism” (nr projektu: MAZOWSZE/0073/19), który planowany jest do realizacji z udziałem dofinansowania publicznego w ramach Konkursu Ścieżka dla Mazowsza (Numer konkursu: Ścieżka dla Mazowsza/2019) przeprowadzanego przez Narodowe Centrum Badań i Rozwoju, ogłaszamy Zapytanie ofertowe nr 1/ŚDM/2019 dotyczące wynajmu mebli laboratoryjnych oraz wyposażenia laboratoryjnego. Zapraszamy do składania ofert.

Zapytanie ofertowe Nr 1/ŚDM/2019
Załącznik 1. Formularz ofertowy do zapytania ofertowego nr 1/ŚDM/2019
Załącznik nr 2. Oświadczenie Wykonawcy dot. spełnienia. warunków uczestnictwa do zapytania ofertowego nr 1/ŚDM/2019
Załącznik nr 3. Oświadczenie Wykonawcy dot. braku powiązań do zapytania ofertowego nr 1/ŚDM/2019
Załącznik nr 4. Opis przedmiotu zamówienia do zapytania ofertowego nr 1/ŚDM/2019.


Project financed by the Polish Agency for Enterprise Development under the Smart Growth Operational Programme 2014-2020.

EuroNanoMed III

Project “Nanoporous-Membranes for Intrathecal (Pseudo)Delivery of Drugs (INTREPIDUS)” co-financed by the National Centre for Research and Development under the EuroNanoMed III Joint Transnational Call for Proposal (2020) for „European Innovative Research & Technological Development Projects in Nanmedicine”

EuroNanoMed III

Project “Nanosystems conjugated with antibody fragments for treating brain infections (TARBRAINFECT)” co-financed by the National Centre for Research and Development under the EuroNanoMed III Joint Transnational Call for Proposal (2018) for „European Innovative Research & Technological Development Projects in Nanmedicine”


Project co-financed by the European Regional Development Fund under the Operational Programme Innovative Economy.


Project “OrganFarm- system for long-term ex vivo organ storage” co-financed by the National Centre for Research and Development under the Smart Growth Operational Programme 2014-2020.


Project “„Red Blood Cells Substitute” co-financed by the the European Regional Development Fund under the Mazovian Regional Operational Program for the years 2014-2020.

NanoSanguis S.A | Rakowiecka 36 | 02-532 Warszawa | Polska
NIP: 7010537389 | Sąd Rejonowy dla m.st. Warszawy XIII Wydział Gospodarczy KRS 595165 | Kapitał zakładowy 185 428,00 zł w całości wpłacony